The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets

Kitano, Mitsutaka; Matsuzaki, Takanobu; Oka, Ryoko; Baba, Kaoru; Noda, Takahiro; Yoshida, Yuki; Satô, Kenji; Kiyota, Kohei; Mizutare, Tohru; Yoshida, Ruriko; Sato, Akihiko; Kamimori, Hiroshi; Shishido, Toetsu; Naito, Akira

doi:10.1111/irv.12760

Cited by 7 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were observed upon infection with IBV with reduced viral titers and clinical signs after a single treatment with peramivir 1-day postinfection [146]. The efficacy of BXM has also been demonstrated in ferrets as decreased viral shedding in the upper respiratory tract and reduced transmission between ferrets in comparison with the placebo and oseltamivir-treated group for IAV and IBV [147][148][149].…”

Section: Ferretssupporting

confidence: 65%

Influenza antivirals and animal models

et al. 2022

View full text Add to dashboard Cite

Influenza A and B viruses are among the most prominent human respiratory pathogens. About 3–5 million severe cases of influenza are associated with 300 000–650 000 deaths per year globally. Antivirals effective at reducing morbidity and mortality are part of the first line of defense against influenza. FDA‐approved antiviral drugs currently include adamantanes (rimantadine and amantadine), neuraminidase inhibitors (NAI; peramivir, zanamivir, and oseltamivir), and the PA endonuclease inhibitor (baloxavir). Mutations associated with antiviral resistance are common and highlight the need for further improvement and development of novel anti‐influenza drugs. A summary is provided for the current knowledge of the approved influenza antivirals and antivirals strategies under evaluation in clinical trials. Preclinical evaluations of novel compounds effective against influenza in different animal models are also discussed.

show abstract

Section: Ferretssupporting

confidence: 65%

Influenza antivirals and animal models

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The simulated results can help design optimal dosage regimes or predict outcomes of clinical trials when used in conjunction with the semi-compartmental modeling function. In actual PK studies, the non-parametric superposition approach has been extensively used [ 23 , 24 , 25 ]. Its assumptions are typically as follows: (a) Application of linear PK to accommodate a change in dose during the multiple dosing regimen; (b) each dose of a drug acts independently of every other dose; (c) the rate of absorption and the average systemic clearance are consistent for each dosing interval [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Determination of Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Parameters of Doxycycline against Edwardsiella ictaluri in Yellow Catfish (Pelteobagrus fulvidraco)

Lin

2021

Antibiotics

View full text Add to dashboard Cite

This study aimed to examine the pharmacokinetics of doxycycline (DC) in yellow catfish (Pelteobagrus fulvidraco) and to calculate related pharmacokinetic–pharmacodynamic (PK/PD) parameters of DC against Edwardsiella ictaluri. The minimum inhibitory concentration of DC against E. ictaluri was determined to be 500 µg/L. As the increase of oral dose from 10 to 40 mg/kg, the area under the concentration vs. time curve from 0 to 96 h (AUC0–96) values were considerably increased in gill, kidney, muscle and skin, and plasma, except in liver. Cmax values exhibited a similar dose-dependent increase trend in plasma and tissues except in liver, but other PK parameters had no apparent dose-dependence. The PK/PD parameter of the ratio of AUC0–96 to minimum inhibitory concentration (AUC0–96h/MIC) was markedly increased in plasma and tissues dose-dependently except in liver, but %T > MIC values were increased only moderately at some dose groups. After receiving the same dose with disparate time intervals from 96 to 12 h, the AUC0–96h/MIC was distinctly increased in plasma and tissues, but the %T > MIC had a decreasing trend. When administering 20 mg/kg with a time interval of 96 h, the AUC0–96h/MIC values were consistently >173.03 h and the %T > MIC values were above 99.47% in plasma and all tissues. These results suggest that administration of DC at 20 mg/kg every 96 h is a preferable regimen in yellow catfish.

show abstract

“…In an A(H3N2) immunodeficient mouse model, the reduction in lung viral titer was the same in mice treated with baloxavir monotherapy (40 mg/kg, single dose) as for mice treated with baloxavir-oseltamivir (40 mg/kg [single dose] and 20 mg/kg [BID], respectively) ( 23 ). For a virus that harbors a PA/I38T or PA/E23K substitution, treatment is unlikely to provide a significant virological benefit to patients; oseltamivir monotherapy or oseltamivir-baloxavir combination therapy may be useful, but only if oseltamivir is effective ( 5 , 24 ). This suggests that alternative treatment options maybe be required to treat a virus that contains a PA/E23K substitution.…”

Section: Discussionmentioning

confidence: 99%

Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model

Koszalka

George

Vijaykrishna

et al. 2022

mBio

View full text Add to dashboard Cite

show abstract

The antiviral effects of baloxavir marboxil against influenza A virus infection in ferrets

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 7 publications

References 41 publications

Influenza antivirals and animal models

Influenza antivirals and animal models

Determination of Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Parameters of Doxycycline against Edwardsiella ictaluri in Yellow Catfish (Pelteobagrus fulvidraco)

Effect of Baloxavir and Oseltamivir in Combination on Infection with Influenza Viruses with PA/I38T or PA/E23K Substitutions in the Ferret Model

Contact Info

Product

Resources

About